Diabetic Neuropathy Market to Rise at 8.9% CAGR and Hit 7.12 Billion by 2026; Severity of the Diseases has Encouraged More Companies, says Fortune Business Insights™

Key Companies Covered in the Diabetic Neuropathy Market Research Report Are Abbott, Eli Lilly and Company, Pfizer.Inc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Astellas Pharma US, Inc. and other key market players


Pune, Nov. 04, 2020 (GLOBE NEWSWIRE) -- The global diabetic neuropathy market size is projected to reach USD 7.12 billion by the end of 2026. The highest prevalence of diabetes will bode well for the market in the coming years. According to a report published by Fortune Business Insights. The market was worth USD 3.61 billion and will exhibit a CAGR of 8.9% during the forecast period, 2019-2026. The market in North America is likely to emerge dominant in the coming years. The high prevalence of diabetic in several countries across this region will aid the growth of the market. As of 2018, the market in North America was worth USD 2.19 billion and this value is likely to increase further in the coming years.

Industry Developments:

July 2019: Laurus Labs Limited announced that it has launched newer version of its pain management capsules for patients suffering from diabetic neuropathy.


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/diabetic-neuropathy-market-100598


Diabetic neuropathy is a severe disorder that mostly occurs in diabetic patients. It leads to nerve damage in legs and feet of the human body. As feet and legs are sensitive parts of the body, there is a huge focus on early detection and precaution of the disease. Besides nerve damages, the disorder has the potential to affect the digestive system and also have adverse effects on the urinary tract and heart. Accounting to the severity of the disease, regulatory authorities are compelled to approve more products and therapeutic procedures associated with the disease.

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.


Click here to get the short-term and long-term impact of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/diabetic-neuropathy-market-100598


Increasing Number of Regulatory Approvals Will Aid Growth

The report encompasses several factors that have contributed to the growth of the market in recent years. Among all factors, the increasing number of product approvals by regulatory authorities across the world has made the highest impact.

In July 2019, Averitas Pharma announced that it received approval from the US Food and Drug Administration for a new product associated with the treatment of neuropathic pain associated with therapeutic procedures. The company received approval for ‘Quentaza’, a drug used to minimize pain in peripheral diabetic neuropathy. Averitas’ latest product will bode well for the market in the foreseeable future.


Quick Buy -  Diabetic Neuropathy Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100598


North America to Emerge Dominant; Increasing Number of Diabetic Patients Will Provide Impetus to Market Growth

The report analyzes the ongoing diabetic neuropathy market trends across North America, Latin America, Asia Pacific, the Middle East and Africa, and Europe. Among these regions, the market in North America is likely to emerge dominant in the coming years. The high prevalence of diabetic in several countries across this region will aid the growth of the market.

As of 2018, the market in North America was worth USD 2.19 billion and this value is likely to increase further in the coming years. The market in Asia Pacific will exhibit the highest CAGR in the coming years, driven by the increasing R&D activities in several countries across this region.


List of Companies Profiled in the Diabetic Neuropathy Market Report:

  • Abbott
  • Eli Lilly and Company
  • Pfizer.Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Janssen Pharmaceuticals, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Astellas Pharma US, Inc.
  • Others


Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/diabetic-neuropathy-market-100598


Diabetic Neuropathy Market Segmentations:

By Disease Type

•              Peripheral

•              Autonomic

•              Proximal

•              Focal

By Drug Class

•              Non-Steroidal Anti-Inflammatory Drugs

•              Opioid

•              Anti-Depressants

•              Anti-Seizure

•              Others

By Distribution Channel

•              Hospitals Pharmacies

•              Retail Pharmacies & Stores

•              Online Pharmacies

By Geography

•              North America (U.S. and Canada)

•              Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

•              Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)

•              Latin America (Brazil, Mexico, and Rest of Latin America)

•              Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)


Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/diabetic-neuropathy-market-100598


Have a Look at Related Reports:

Anti-Fungal Drugs Market Share & Industry Analysis, By Drug Type (Echinocandins, Azoles, Polyenes, and Allylamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis, and Others), By Route of Administration (Oral, Topical, and Parenteral), By Distribution Channel (Hospital Pharmacies, Retails Pharmacies & Drug Stores, and Others), and Regional Forecast, 2020-2027

Anti-Inflammatory Drugs Market Share & Industry Analysis, By Drug Class (Anti-inflammatory Biologics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids), By Application (Autoimmune Inflammatory Diseases (Rheumatoid Arthritis Psoriasis), Respiratory Diseases), By Route of Administration (Oral, Injection, Inhalation, and Topical), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), and Regional Forecast, 2020-2027

Nebulizer Market Share & COVID-19 Impact Analysis, By Type (Jet Nebulizer, Ultrasonic Nebulizer, and Mesh Nebulizer) By Modality (Portable, and Table-top) By End User (Hospitals, Clinics, and Homecare Settings), and Regional Forecast, 2020-2027

Cystic Fibrosis Market Share & Covid-19 Impact Analysis, By Drug Class (Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement, and Others), By Route of Administration (Oral, and Parenteral), By Distribution Channel (Retail Pharmacies & Drug Stores, Online Pharmacies, and Hospital Pharmacies), and Regional Forecast, 2020-2027

Sleep Apnea Devices Market Share & Covid-19 Impact Analysis, By Device Type (Therapeutic Devices, and Diagnostic Devices), By End User (Sleep Laboratories & Clinics, and Homecare & Other Settings), and Regional Forecast, 2020-2027


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.


Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs


Press Release: https://www.fortunebusinessinsights.com/press-release/diabetic-neuropathy-market-9858